Macrophage Pharma appoints Dr Michael Moore as Chairman

Dr Michael Moore

Macrophage Pharma Limited, a company focused on the discovery and development of next-generation small molecules aiming to modulate immune responses to combat cancer and other diseases, announces the appointed Dr Michael Moore as non-executive Chairman with immediate effect./p>

Commenting on the appointment, Steven Powell, CEO of Macrophage Pharma, said: “Michael’s outstanding track record in building both private and public biotech companies, as well as his expertise and insight into the field of immunology, will be invaluable as we develop and commercialise our proprietary Esterase Sensitive Motif (ESM) platform and evolve into a leading immunology company.”

Dr Michael Moore has extensive experience in drug discovery and development and is currently a non-executive director of several private and public bioscience companies, including Mission Therapeutics, of which he was Founder Chairman, NASDAQ-listed Trillium Therapeutics Inc and Mironid Limited. He is currently Chairman of Chronos Therapeutics and was Founder Chairman of PsiOxus Therapeutics. Dr Moore was previously CEO of Piramed, acquired by Roche in 2008, and Research Director and CSO of Xenova Group plc. Prior to joining the UK biotechnology sector, he had an extensive academic research career, principally at the Paterson Institute for Cancer Research and the University of Manchester Medical School, where he was Honorary Reader in immunology and oncology. Dr Moore holds PhD and DSc degrees from the University of Nottingham, fellowship of the Royal College of Pathologists and is a past Chairman of Cancer Research UK’s drug discovery committee.